Evidence map›Paper›PMID 42411284›Full record

ArticleJournal of chemical information and modeling2026

Bridging between Structure-Based and Data-Driven Affinity Prediction.

Alžbeta Kubincová, David L Mobley

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alžbeta KubincováDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, California92697, United States.ORCID 0000-0001-6518-681X
David L MobleyDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, California92697, United States.ORCID 0000-0002-1083-5533

Funding

Accelerating drug discovery via ML-guided iterative design and optimizationR35GM148236 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI David Lowell Mobley · 2023 to 2026
$2.2M
NIGMS NIH HHS R35 GM148236
6 · The paper itself

Abstract

Protein-ligand binding affinity prediction is central in computer-aided drug design, and a wide range of physics-based, empirical, and machine learning (ML) tools have been developed for this purpose. Scientists are often tasked with choosing an optimal tool for a given discovery problem, which can be difficult. Physical models typically perform best in the absence of target-specific data but are often outperformed by ML models as the amount of data on a given target grows. Here, we introduce a method to smoothly transition from physics-based to knowledge-based predictions based on the uncertainty of each model. We apply this framework to combine docking scores with predictions from a Gaussian Process model trained on binding affinities from two industrial data sets. We show that combining structure-based and ML models significantly improves the prediction accuracy if training data is limited, whereas the weighting smoothly shifts from docking to ML as more data is acquired. We also show that structure-based methods, being insensitive to the distribution of binders across chemical space, can improve generalizability to new chemistries and increase the hit rate in active learning screens where the binder density varies among scaffolds in a virtual library. Thus, integrating predictions from multiple tools not only optimizes the use of limited experimental data but also ensures more robust performance compared to reliance on a single model.

Indexed as

Molecular Docking SimulationProteinsDrug DesignLigandsMachine LearningPrediction AlgorithmsPredictive Learning ModelsProtein BindingLigandsProteins

Identifiers

PMID42411284
PMCPMC13544569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.